RENEW OR SUBSCRIBE TO PPM
Subscription is FREE for qualified healthcare professionals in the US.
12 Articles in Volume 16, Issue #10
2016 Practical Clinical Advances: Ketamine and Metformin
Case Challenge: Amniotic Allograft Reduces Joint and Soft Tissue Pain
Challenges of Treating Young Patients With a Terminal Prognosis
Defining Palliative Care
Discussing Benefits of Palliative Care
Evaluation of Antiemetic Pharmacotherapy in the Setting of Opioid Withdrawal
Fibromyalgia, Chronic Fatigue, and Chronic Fatigue Syndrome
Gabapentin Dosing for Neuropathic Pain
IV Acetaminophen Reduces Need for Opioids in Burn Patients
Opioid-Induced Constipation: New and Emerging Therapies—Update 2016
Osteopathic Treatment Considerations For Head, Neck, and Facial Pain
Tips From the Field: Deconstructing the Art of Headache Medicine

Evaluation of Antiemetic Pharmacotherapy in the Setting of Opioid Withdrawal

As the dose of opioids used for chronic pain management decreases, patients who are put on a weaning program may experience withdrawal symptoms. Ondansetron, a well-known antiemetic, may be a safe and effective option for managing these symptoms.
Page 3 of 3

Conclusion

When choosing an antiemetic for the management of opioid withdrawal symptoms, clinicians should be cognizant of the safety, efficacy, and abuse potential of each therapy. Considering available literature, ondansetron appears to be preferred over dopamine-receptor antagonists in the treatment of opioid withdrawal symptoms, but evidence is lacking, and further investigation is warranted.

Last updated on: December 27, 2016
Continue Reading:
Osteopathic Treatment Considerations For Head, Neck, and Facial Pain

Join The Conversation

Register or Log-in to Join the Conversation
SHOW MAIN MENU
SHOW SUB MENU